Current disease modifying approaches to treat Parkinson's disease

Natale Belluardo, Giuseppa Mudo', Valentina Di Liberto, Mart Saarma, Ove Eriksson, Johanna Mäkelä, Dan Lindholm

Risultato della ricerca: Article

49 Citazioni (Scopus)

Abstract

Parkinson's disease (PD is a progressive neurological disorder characterized by the degeneration and death of midbrain dopamine and non-dopamine neurons in the brain leading to motor dysfunctions and other symptoms, which seriously influence the quality of life of PD patients. The drug L-dopa can alleviate the motor symptoms in PD, but so far there are no rational therapies targeting the underlying neurodegenerative processes. Despite intensive research, the molecular mechanisms causing neuronal loss are not fully understood which has hampered the development of new drugs and disease-modifying therapies. Neurotrophic factors are by virtue of their survival promoting activities attract candidates to counteract and possibly halt cell degeneration in PD. In particular, studies employing glial cell line-derived neurotrophic factor (GDNF) and its family member neurturin (NRTN), as well as the recently described cerebral dopamine neurotrophic factor (CDNF) and the mesencephalic astrocyte-derived neurotrophic factor (MANF) have shown positive results in protecting and repairing dopaminergic neurons in various models of PD. Other substances with trophic actions in dopaminergic neurons include neuropeptides and small compounds that target different pathways impaired in PD, such as increased cell stress, protein handling defects, dysfunctional mitochondria and neuroinflammation. In this review, we will highlight the recent developments in this field with a focus on trophic factors and substances having the potential to beneficially influence the viability and functions of dopaminergic neurons as shown in preclinical or in animal models of PD.
Lingua originaleEnglish
pagine (da-a)1365-1379
Numero di pagine15
RivistaCellular and Molecular Life Sciences
Volume73
Stato di pubblicazionePublished - 2015

Fingerprint

Dopaminergic Neurons
Nerve Growth Factors
Parkinson Disease
Dopamine
Neurturin
Glial Cell Line-Derived Neurotrophic Factor
Levodopa
Mesencephalon
Heat-Shock Proteins
Nervous System Diseases
Neuropeptides
Astrocytes
Pharmaceutical Preparations
Mitochondria
Animal Models
Quality of Life
Neurons
Survival
Brain
Therapeutics

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Cell Biology
  • Cellular and Molecular Neuroscience
  • Pharmacology
  • Molecular Biology

Cita questo

Current disease modifying approaches to treat Parkinson's disease. / Belluardo, Natale; Mudo', Giuseppa; Di Liberto, Valentina; Saarma, Mart; Eriksson, Ove; Mäkelä, Johanna; Lindholm, Dan.

In: Cellular and Molecular Life Sciences, Vol. 73, 2015, pag. 1365-1379.

Risultato della ricerca: Article

Belluardo, Natale ; Mudo', Giuseppa ; Di Liberto, Valentina ; Saarma, Mart ; Eriksson, Ove ; Mäkelä, Johanna ; Lindholm, Dan. / Current disease modifying approaches to treat Parkinson's disease. In: Cellular and Molecular Life Sciences. 2015 ; Vol. 73. pagg. 1365-1379.
@article{5b1b71c0d8684525a4b78946c9160340,
title = "Current disease modifying approaches to treat Parkinson's disease",
abstract = "Parkinson's disease (PD is a progressive neurological disorder characterized by the degeneration and death of midbrain dopamine and non-dopamine neurons in the brain leading to motor dysfunctions and other symptoms, which seriously influence the quality of life of PD patients. The drug L-dopa can alleviate the motor symptoms in PD, but so far there are no rational therapies targeting the underlying neurodegenerative processes. Despite intensive research, the molecular mechanisms causing neuronal loss are not fully understood which has hampered the development of new drugs and disease-modifying therapies. Neurotrophic factors are by virtue of their survival promoting activities attract candidates to counteract and possibly halt cell degeneration in PD. In particular, studies employing glial cell line-derived neurotrophic factor (GDNF) and its family member neurturin (NRTN), as well as the recently described cerebral dopamine neurotrophic factor (CDNF) and the mesencephalic astrocyte-derived neurotrophic factor (MANF) have shown positive results in protecting and repairing dopaminergic neurons in various models of PD. Other substances with trophic actions in dopaminergic neurons include neuropeptides and small compounds that target different pathways impaired in PD, such as increased cell stress, protein handling defects, dysfunctional mitochondria and neuroinflammation. In this review, we will highlight the recent developments in this field with a focus on trophic factors and substances having the potential to beneficially influence the viability and functions of dopaminergic neurons as shown in preclinical or in animal models of PD.",
keywords = "Dopamine neurons; ER stress; Mitochondria; Neuroinflammation; Neuropeptides; Neurotrophic factors; Protein aggregation; {\^I}±-Synuclein; Molecular Medicine; Molecular Biology; Pharmacology; Cellular and Molecular Neuroscience; Cell Biology",
author = "Natale Belluardo and Giuseppa Mudo' and {Di Liberto}, Valentina and Mart Saarma and Ove Eriksson and Johanna M{\"a}kel{\"a} and Dan Lindholm",
year = "2015",
language = "English",
volume = "73",
pages = "1365--1379",
journal = "Cellular and Molecular Life Sciences",
issn = "1420-682X",
publisher = "Birkhauser Verlag Basel",

}

TY - JOUR

T1 - Current disease modifying approaches to treat Parkinson's disease

AU - Belluardo, Natale

AU - Mudo', Giuseppa

AU - Di Liberto, Valentina

AU - Saarma, Mart

AU - Eriksson, Ove

AU - Mäkelä, Johanna

AU - Lindholm, Dan

PY - 2015

Y1 - 2015

N2 - Parkinson's disease (PD is a progressive neurological disorder characterized by the degeneration and death of midbrain dopamine and non-dopamine neurons in the brain leading to motor dysfunctions and other symptoms, which seriously influence the quality of life of PD patients. The drug L-dopa can alleviate the motor symptoms in PD, but so far there are no rational therapies targeting the underlying neurodegenerative processes. Despite intensive research, the molecular mechanisms causing neuronal loss are not fully understood which has hampered the development of new drugs and disease-modifying therapies. Neurotrophic factors are by virtue of their survival promoting activities attract candidates to counteract and possibly halt cell degeneration in PD. In particular, studies employing glial cell line-derived neurotrophic factor (GDNF) and its family member neurturin (NRTN), as well as the recently described cerebral dopamine neurotrophic factor (CDNF) and the mesencephalic astrocyte-derived neurotrophic factor (MANF) have shown positive results in protecting and repairing dopaminergic neurons in various models of PD. Other substances with trophic actions in dopaminergic neurons include neuropeptides and small compounds that target different pathways impaired in PD, such as increased cell stress, protein handling defects, dysfunctional mitochondria and neuroinflammation. In this review, we will highlight the recent developments in this field with a focus on trophic factors and substances having the potential to beneficially influence the viability and functions of dopaminergic neurons as shown in preclinical or in animal models of PD.

AB - Parkinson's disease (PD is a progressive neurological disorder characterized by the degeneration and death of midbrain dopamine and non-dopamine neurons in the brain leading to motor dysfunctions and other symptoms, which seriously influence the quality of life of PD patients. The drug L-dopa can alleviate the motor symptoms in PD, but so far there are no rational therapies targeting the underlying neurodegenerative processes. Despite intensive research, the molecular mechanisms causing neuronal loss are not fully understood which has hampered the development of new drugs and disease-modifying therapies. Neurotrophic factors are by virtue of their survival promoting activities attract candidates to counteract and possibly halt cell degeneration in PD. In particular, studies employing glial cell line-derived neurotrophic factor (GDNF) and its family member neurturin (NRTN), as well as the recently described cerebral dopamine neurotrophic factor (CDNF) and the mesencephalic astrocyte-derived neurotrophic factor (MANF) have shown positive results in protecting and repairing dopaminergic neurons in various models of PD. Other substances with trophic actions in dopaminergic neurons include neuropeptides and small compounds that target different pathways impaired in PD, such as increased cell stress, protein handling defects, dysfunctional mitochondria and neuroinflammation. In this review, we will highlight the recent developments in this field with a focus on trophic factors and substances having the potential to beneficially influence the viability and functions of dopaminergic neurons as shown in preclinical or in animal models of PD.

KW - Dopamine neurons; ER stress; Mitochondria; Neuroinflammation; Neuropeptides; Neurotrophic factors; Protein aggregation; α-Synuclein; Molecular Medicine; Molecular Biology; Pharmacology; Cellular and Molecular Neuroscience; Cell Biology

UR - http://hdl.handle.net/10447/283390

UR - http://link.springer.de/link/service/journals/00018/index.htm

M3 - Article

VL - 73

SP - 1365

EP - 1379

JO - Cellular and Molecular Life Sciences

JF - Cellular and Molecular Life Sciences

SN - 1420-682X

ER -